Vaccination of children against coronavirus infection caused by SARS-CoV-2

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The novel coronavirus infection (COVID-19) is currently a widespread disease in all countries of the world. The adult population is predominantly involved in the epidemic process. In children, the disease proceeds, as a rule, in asymptomatic, mild and moderate forms. However, severe forms of the disease with the development of adverse outcomes are possible. Severe forms of infection are more likely to develop in children under the age of 1 year and older than 12 years. The risk group for a non-smooth course and adverse outcomes are children with concomitant diseases: genetic, neurological, metabolic disorders, congenital heart defects, obesity, diabetes mellitus, bronchial asthma and other chronic lung diseases, sickle cell anemia, oncopathology, immunodeficiency states. At present, various types of vaccines are used for specific prevention in the world: based on M-RNA technologies, vectorial, inactivated. These vaccines are effective and safe in reducing the burden of disease in eligible adolescents. Despite the emergence of new strains of circulating viruses, vaccines continue to be effective in preventing severe infections, hospitalization and death.

作者简介

Susanna Kharit

St. Petersburg State Pediatric Medical University; Children’s Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency

编辑信件的主要联系方式.
Email: kharit-s@mail.ru
ORCID iD: 0000-0002-2371-2460

MD, PhD, Dr. Sci. (Med.), Professor of the Department of Infectious Diseases in Children of AF and DPO, St. Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation; Head of the Research Institute of Vaccination Prevention and Post-Vaccination Pathology, Children's Scientific and Clinical Center for Infectious Diseases, FMBA

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Vladimir Timchenko

St. Petersburg State Pediatric Medical University

Email: timchenko220853@yandex.ru
ORCID iD: 0000-0002-4068-1731

MD, PhD, Dr. Sci. (Med.), Professor, Head of the Professor M.G. Danilevich Department of Infectious Diseases in Children

俄罗斯联邦, Saint Petersburg

Tatyana Chernova

St. Petersburg State Pediatric Medical University

Email: t-chernova@mail.ru
ORCID iD: 0000-0003-4845-3757

MD, PhD, Assistant Professor

俄罗斯联邦, Saint Petersburg

Oksana Bulina

St. Petersburg State Pediatric Medical University

Email: oksanabulina@yandex.ru
ORCID iD: 0000-0002-2997-7777

MD, PhD, Assistant Professor

俄罗斯联邦, Saint Petersburg

参考

  1. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19): Vremennye metodicheskie rekomendatsii. Versiya 11. Moscow: Ministerstvo zdravookhraneniya RF, 2021. (In Russ.)
  2. Aleksandrovich YuS, Alekseeva EI, Bakradze MD, et al. Metodicheskie rekomendatsii “Osobennosti klinicheskikh proyavlenii i lecheniya zabolevaniya, vyzvannogo novoi koronavirusnoi infektsiei (COVID-19) u detei”. Versiya 2. Moscow: Ministerstvo zdravookhraneniya RF, 2020. 73 p. (In Russ.)
  3. Bregel LV, Kostik MM, Fell LZ, et al. Kawasaki disease and multisystem inflammatory syndrome in children with COVID-19 infection. “Pediatria” named after G.N. Speransky. 2020;99(6):209–219. (In Russ.) doi: 10.24110/0031-403X-2020-99-6-209-219
  4. Gorelov AV, Nikolaeva SV, Akimkin VG. Сoronavirus infection COVID-19 in children in the Russian Federation. Infectious diseases. 2020;18(3):15–20. (In Russ.) doi: 10.20953/1729-9225-2020-3-15-20
  5. Drapkina OM, Gorshkov AYu, Yakimova YuV, et al. Vremennye metodicheskie rekomendatsii “Poryadok provedeniya vaktsinatsii protiv novoi koronavirusnoi infektsii (COVID-19)”. 2022. 80 p. Moscow: Ministerstvo zdravookhraneniya RF, 2022. 80 p. (In Russ.)
  6. Ivanov DO, Petrenko YV, Reznik VA, et al. New coronavirus infection in a child at the age of 2 years 4 months with acute lymphoblastic leukemia (fatal case). Pediatrician (St. Petersburg). 2022;13(3):73–82. (In Russ.) doi: 10.17816/PED13373-82
  7. Ivanov DO, Petrenko YuV, Reznik VA, et al. Characteristics of new coronavirus infection in patients with acute myeloid leukemia. Clinical Practice in Pediatrics. 2021;16(3):121–129. (In Russ.) doi: 10.20953/1817-7646-2021-3-121-129
  8. Kantemirova MG, Novikova YuYu, Ovsyannikov DYu, et al. Children’s multisystem inflammatory syndrome, associated with a new coronavirus infection (COVID-19): relevant information and clinical observation. Pediatric pharmacology. 2020;17(3):219–229. (In Russ.) doi: 10.15690/pf.v17i3.2126
  9. Kataeva IS, Bashketova NS, Kim AV, Sharafutdinova LL. Analiz infektsionnoi zabolevaemosti detskogo naseleniya Sankt-Peterburga, v tom chisle v period pandemii COVID-19. Children’s medicine of the North-West. 2021;9(3):88–89. (In Russ.)
  10. Lobzin YuV, Vilnits AA, Kostik MM, et al. Pediatric multisystem inflammatory syndrome associated with a new coronavirus infection: unresolved issues. Journal Infectology. 2021;13(1):13–20. (In Russ.) doi: 10.22625/2072-6732-2021-13-1-13-20
  11. Petrov OI, Pavelkina VF, Shirmankina MV, et al. Kliniko-ehpidemiologicheskie osobennosti novoi koronavirusnoi infektsii COVID-19 u detei. Modern Problems of Science and Education. Surgery. 2022;(3). Available at: https://science-education.ru/ru/article/view?id=31768 (In Russ.)
  12. Chernova TM, Pavlova EB, Timchenko VN, et al. Clinical and epidemiological characteristics and effectiveness of antiviral therapy for COVID-19 in children: The experience of the first year of the pandemic. Acta Biomedica Scientifica. 2021;6(6–2):18–28. (In Russ.) doi: 10.29413/ABS.2021-6.6-2.3
  13. Chernova TM, Timchenko VN, Barakina EV, et al. Outcome of COVID-19 in children: results of a 12-month follow-up. Journal Infectology. 2022;14(2):96–106. (In Russ.) doi: 10.22625/2072-6732-2022-14-2-96-106
  14. Shakmaeva MA, Chernova TM, Timchenko VN, et al. Features of a new Coronavirus infection in children of different ages. Children infections. 2021;20(2):5–9. (In Russ.) doi: 10.22627/2072-8107-2021-20-2-5-9
  15. Agrawal B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front Immunol. 2019;10:2631. doi: 10.3389/fimmu.2019.02631
  16. Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. World Health Organization, 2021. 44 р.
  17. Boehmer TK, DeVies J, Caruso E, et al. Changing age distribution of the COVID-19 pandemic — United States, May–August 2020. MMWR. 2020;69(39):1404–1409. doi: 10.15585/mmwr.mm6939e1
  18. Briefing Document: Moderna COVID-19 Vaccine EUA amendment for use in children 6 months through 17 years of age. Vaccines and Related Biological Products Advisory Committee Meeting; June 14–15, 2022. 189 р. Available at: https://www.fda.gov/media/159189/download
  19. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatrica. 2021;110(7):2208–2211. doi: 10.1111/apa.15870
  20. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 States, March 1, 2020 — August 14, 2021. MMWR. 2021;70(36):1255–1260. doi: 10.15585/mmwr.mm7036e2
  21. Fernandes EG, López-Lopes GIS, Silva VO, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children. Rev Inst Med Trop São Paulo. 2021;63: e83. doi: 10.1590/S1678-9946202163083
  22. Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim recommendations of the Advisory Committee on Immunization Practices for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 months — 5 years — United States, June 2022. MMWR. 2022;71(26): 859–868. doi: 10.15585/mmwr.mm7126e2
  23. García-Salido А. Three hypotheses about children COVID-19. Pediatr Infect Dis J. 2020;39(7):e157. doi: 10.1097/INF.0000000000002701
  24. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(12):1645–1653. doi: 10.1016/S1473-3099(21)00319-4
  25. Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA vaccine safety among children aged 6 months — 5 years — United States, June 18, 2022 — August 21, 2022. MMWR. 2022;71(35):1115–1120. doi: 10.15585/mmwr.mm7135a3
  26. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing updated 21 Jan 2022. World Health Organization, 2022. 16 р.
  27. Israeli Ministry of Health. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 [Press release]. Jerusalem, Israel: Israeli Ministry of Health, 2021.
  28. Lessler J, Grabowski MK, Grantz KH, et al. Household COVID-19 risk and in-person schooling. Science. 2021;372 (6546):1092–1097. doi: 10.1126/science.abh2939
  29. Lopez AS, Hill M, Antezano J. Transmission dynamics of COVID-19 outbreaks associated with child care facilities — Salt Lake City, Utah, April–July 2020. MMWR. 2020;69(37):1319–1323. doi: 10.15585/mmwr.mm6937e3
  30. Most ZM, Hendren N, Drazner MH, Trish M. Perl striking similarities of multisystem inflammatory syndrome in children and a myocarditis-like syndrome in adults overlapping manifestations of COVID-19. Circulation. 2021; 143(1):4–6. doi: 10.1161/CIRCULATIONAHA.120.050166
  31. Mysore V, Cullere Х, Settles ML, et al. Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. Med. 2021;2(9): 1050–1071.e7. doi: 10.1016/j.medj.2021.08.004
  32. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. MMWR. 2021;69(51–52): 1653–1656. doi: 10.15585/mmwr.mm695152e1
  33. Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the 2 ISARIC Global follow-up protocol: A prospective cohort study. Eur Respir J. 2022;59(2):2101341 doi: 10.1183/13993003.01341-2021
  34. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10): 1115–1117. doi: 10.1001/jamacardio.2021.2821
  35. Summary of product characteristics. European Medicines Agency, 2021. 136 p.
  36. www.cdc.gov [Internet]. Vaccination Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events. CDC, COVID-19. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html
  37. Vadrevu KM, Reddy S, Jogdand H, et al. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. Lancet Infect Dis. 2022;22(9): 1303–1312. doi: 10.1016/S1473-3099(22)00307-3
  38. Wallace M, Woodworth KR, Gargano JW, et al The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021. MMWR. 2021;70(20):749–752. doi: 10.15585/mmwr.mm7020e1
  39. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021. MMWR. 2021;70(45):1579–1583. doi: 10.15585/mmwr.mm7045e1
  40. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19 an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355–368. doi: 10.1097/INF.0000000000002660

版权所有 © Eco-Vector, 2023


 


##common.cookie##